DPP-4 inhibitor and biguanide combination

This page covers all DPP-4 inhibitor and biguanide combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting DPP-4.

Targets

DPP-4

Phase 3 pipeline (1)

• Matching Placebo to Sita/Met FDC · Merck Sharp & Dohme LLC · Diabetes
  Sita/Met FDC combines sitagliptin, a dipeptidyl peptidase-4 inhibitor, with metformin, a biguanide, to improve glycemic control in patients with type 2 diabetes.